A Historic Shift in Medicare Coverage
After decades of excluding weight-loss medications from coverage, Medicare is finally opening the door. As of January 1, 2026, Medicare Part D plans are required to cover FDA-approved anti-obesity medications for enrollees who meet specific clinical criteria — a change that could affect an estimated 15 million Medicare beneficiaries with obesity.
The policy change stems from the Treat and Reduce Obesity Act, which was signed into law in late 2025 after years of bipartisan advocacy. The law recognizes obesity as a chronic disease rather than a lifestyle choice and mandates that Medicare cover evidence-based treatments, including prescription medications.
Which Drugs Are Covered?
Medicare Part D plans must cover at least two FDA-approved anti-obesity medications. The specific drugs covered vary by plan, but the most commonly included are:
- Wegovy (semaglutide 2.4 mg) — The most widely prescribed GLP-1 weight-loss injection
- Zepbound (tirzepatide) — A dual GIP/GLP-1 receptor agonist with strong clinical data
- Contrave (naltrexone-bupropion) — An oral combination pill, typically covered as a lower-cost alternative
- Qsymia (phentermine-topiramate) — Another oral option with established efficacy
Plans are not required to cover every obesity drug on the market, but they must offer at least two options across different drug classes.
Who Qualifies?
To receive coverage, Medicare beneficiaries must meet the following criteria:
- BMI of 30 or higher (obesity), OR
- BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease, or osteoarthritis)
- A prescription from an enrolled Medicare provider
- Completion of prior authorization, which may include documentation of previous weight-management attempts
"This is the most significant expansion of obesity treatment coverage in Medicare's history. Millions of seniors who could not afford these medications will now have access," said Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital.
What Will It Cost?
Under the new coverage mandate, Medicare beneficiaries can expect to pay:
- Preferred brand copay: $35-$80 per month (for plans that place the drug on a preferred tier)
- Non-preferred brand copay: $80-$150 per month
- Specialty tier: Up to 25% coinsurance, but capped at the Part D out-of-pocket maximum of $2,000 per year under the Inflation Reduction Act
This represents a dramatic improvement over the previous situation, where Medicare beneficiaries had to pay the full retail price — often over $1,000 per month — entirely out of pocket.
How to Get Started
If you are a Medicare beneficiary interested in weight-loss medication coverage, here are the steps:
- Step 1: Schedule an appointment with your primary care physician to discuss whether anti-obesity medication is appropriate for you
- Step 2: Check your specific Part D plan's formulary to see which drugs are covered and at what tier
- Step 3: Complete any required prior authorization — your doctor's office can usually handle this for you
- Step 4: Fill your prescription at a network pharmacy
If your current Part D plan does not cover the medication your doctor recommends, you may be able to request a formulary exception or switch plans during the next Open Enrollment Period (October 15 - December 7).
The Bigger Picture
The Congressional Budget Office estimates that covering weight-loss drugs under Medicare will cost approximately $35 billion over 10 years. However, proponents argue that the investment will be more than offset by reductions in obesity-related healthcare costs, including fewer hospitalizations for heart attacks, strokes, and diabetes complications. Obesity-related conditions currently cost Medicare an estimated $170 billion annually.
For millions of older Americans struggling with obesity, this policy change represents hope that effective treatment is finally within reach.
